Industry Attorneys Criticize FDA’s Emerging Signals Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
A recent draft guidance from FDA establishing a process for issuing early public warnings of possible safety risks linked to devices is raising the hackles of industry attorneys and advocates who say the warnings could confuse patients, lead them to avoid appropriate use of devices and increase the likelihood of frivolous lawsuits.
You may also be interested in...
FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks
In a draft guidance, FDA explains how it plans to communicate signs of postmarket device risks before it has performed a full analysis or developed specific recommendations. Public health advocates say it is a positive move to get ahead of potential safety problems early. The agency is seeking comment from companies on whether it needs to consult with firms prior to releasing information on emerging signals about their devices.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.